Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 71

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 71
---
4 as a new hire equity grant. These RSUs vest 25% on January 29, 2025, 25% on January 29, 2026, 25% on January 29, 2027, and 25% on January 29, 2028.

(5) The amounts represent the grant date fair value calculated in accordance with FASB ASC Topic 718 and, (a) in the case of RSUs granted on March 14, 2024, are based on the closing price of our common stock on the Nasdaq Global Select Market on March 14, 2024 of $21.32, (b) in the case of PSUs that vest based on performance and market conditions that were granted on March 14, 2024, are based on a weighted value per award of $23.81 (67% of the units have a performance condition which are valued based on the closing price of our common stock on the Nasdaq Global Select Market on March 14, 2023 of $21.32 and the other 33% of the units have a market condition and are valued using a Monte Carlo valuation model which resulted in a value of $28.87), (c) in the case of RSUs granted to Mr. Leffler on January 29, 2024, are based on the closing price of our common stock on the Nasdaq Global Select Market on January 29, 2024 of $22.72.

Narrative Disclosure to Summary Compensation Table and 2024 Fiscal Year Grants of Plan-Based Awards Table

We have entered into standard form employment agreements with each of our NEOs other than Mr. Diaz whose employment agreement is discussed below. Pursuant to these standard form employment agreements, which have no defined term, either party may terminate employment without cause at any time upon a specified period of written notice to the other party or immediately with cause upon written notice to the other party. Each employment agreement also provides that the employee will not disclose confidential information of ours during and after employment and includes standard restrictive covenants. Since the dates we entered into each of these employment agreements with our NEOs, the compensation paid to each NEO may have been increased and additional equity awards may have been granted, the most recent of which are discussed below.

49

We have also entered into a Severance and Change of Control Agreement with each NEO other than Mr. Diaz. These agreements, which are discussed below under “Potential Payments Upon Termination or